Study prodromal Parkinson signs in GBA1 mutation carriers
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study looks at early (before full disease) Parkinson-like symptoms in people who carry a specific genetic change called GBA1. It may help researchers understand who could develop Parkinson’s and how early signs can be tracked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are willing to participate in the study.
- You do not currently have Parkinson’s disease.
- You do not have dementia (memory/thinking problems severe enough to be diagnosed as dementia).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking for ways to find new drugs that may help people with Parkinson’s caused by changes in the GBA gene. It may also include people with Gaucher disease and healthy volunteers, using blood and possibly skin samples.
This study looks at people with Parkinson’s who carry a specific genetic change in the GBA gene. It uses several tests (including brain scans) to understand the disease better and may help guide future treatments.
This study looks at non-motor symptoms (like mood, thinking, or sleep problems) in people with a specific genetic change linked to Parkinson's disease. It compares those with the GBA gene change to those without it to see how symptoms differ.
This study uses blood tests and brain imaging to understand how Parkinson's disease spreads. It may help find early signs and new treatment targets.
This trial tests a gene therapy product called VGN-R08b for people with Parkinson's disease who have a specific genetic change (GBA1 mutation). The goal is to help improve movement and daily function.
This study tests if a drug called prasinezumab can help prevent memory and thinking problems in people with Parkinson's disease who have a specific change in their GBA gene. It looks at whether the treatment can slow down cognitive decline.
Hear when a new Gaucher Disease Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.